These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 23574635)

  • 21. Statin, the black box.
    Hatem S; Boccara F
    Arch Cardiovasc Dis; 2008 Jun; 101(6):377-9. PubMed ID: 18809149
    [No Abstract]   [Full Text] [Related]  

  • 22. Safety and effectiveness of the association ezetimibe-statin (E-S) versus high dose rosuvastatin after acute coronary syndrome: the SAFE-ES study.
    Deharo P; Pankert M; Quilici J; Grosdidier C; Verdier V; Bonnet G; Morange P; Alessi MC; Bonnet JL; Cuisset T
    Ann Cardiol Angeiol (Paris); 2014 Sep; 63(4):222-7. PubMed ID: 24861503
    [TBL] [Abstract][Full Text] [Related]  

  • 23. One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.
    Ferdinand KC; Davidson MH; Kelly MT; Setze CM
    Am J Cardiovasc Drugs; 2012 Apr; 12(2):117-25. PubMed ID: 22263674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II.
    Ballantyne CM; Bertolami M; Hernandez Garcia HR; Nul D; Stein EA; Theroux P; Weiss R; Cain VA; Raichlen JS
    Am Heart J; 2006 May; 151(5):975.e1-9. PubMed ID: 16644314
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cardiovascular event reduction and adverse events among subjects attaining low-density lipoprotein cholesterol <50 mg/dl with rosuvastatin. The JUPITER trial (Justification for the Use of Statins in Prevention: an Intervention Trial Evaluating Rosuvastatin).
    Hsia J; MacFadyen JG; Monyak J; Ridker PM
    J Am Coll Cardiol; 2011 Apr; 57(16):1666-75. PubMed ID: 21492764
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Drug safety evaluation of rosuvastatin.
    Toth PP; Dayspring TD
    Expert Opin Drug Saf; 2011 Nov; 10(6):969-86. PubMed ID: 21999163
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lipid levels and low-density lipoprotein cholesterol goal attainment in diabetic patients: rosuvastatin compared with other statins in usual care.
    Harley CR; Gandhi SK; Heien H; McDonough K; Nelson SP
    Expert Opin Pharmacother; 2008 Apr; 9(5):669-76. PubMed ID: 18345946
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials.
    Wlodarczyk J; Sullivan D; Smith M
    Am J Cardiol; 2008 Dec; 102(12):1654-62. PubMed ID: 19064019
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effects of rosuvastatin and atorvastatin on the apolipoprotein B/apolipoprotein A-1 ratio in patients with an acute coronary syndrome: The CENTAURUS trial design.
    Lablanche JM; Danchin N; Farnier M; Tedgui A; Vicaut E; Alonso J; Crean P; Leone A; Morais J; Santini M; Licour M; Farah M; Tardif JC
    Arch Cardiovasc Dis; 2008 Jun; 101(6):399-406. PubMed ID: 18809153
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [Clinical trials with rosuvastatin: efficacy and safety of its use].
    Schweiger C
    Ital Heart J; 2003 Dec; 4 Suppl 7():33S-46S. PubMed ID: 14983745
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expanding options with a wider range of rosuvastatin doses.
    Olsson AG
    Clin Ther; 2006 Nov; 28(11):1747-63. PubMed ID: 17212997
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rosuvastatin: a new inhibitor of HMG-coA reductase for the treatment of dyslipidemia.
    Rosenson RS
    Expert Rev Cardiovasc Ther; 2003 Nov; 1(4):495-505. PubMed ID: 15030249
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Role of rosuvastatin in current lipid-lowering therapy].
    Abel T; Fehér J
    Orv Hetil; 2010 Aug; 151(35):1424-8. PubMed ID: 20719717
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Rosuvastatin-induced high-density lipoprotein changes in patients who underwent percutaneous coronary intervention for non-ST-segment elevation acute coronary syndrome.
    Yun KH; Shin SN; Ko JS; Rhee SJ; Kim NH; Oh SK; Jeong JW
    J Cardiol; 2012 Nov; 60(5):383-8. PubMed ID: 22884684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rosuvastatin along the cardiovascular continuum: from JUPITER to AURORA.
    Barrios V; Escobar C
    Expert Rev Cardiovasc Ther; 2009 Nov; 7(11):1317-27. PubMed ID: 19900015
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of rosuvastatin in reducing LDL-C and target LDL-C goal attainment in real-world clinical practice.
    Gandhi SK; Järbrink K; Fox KM; Brandrup-Wognsen G
    Curr Med Res Opin; 2009 Dec; 25(12):2817-28. PubMed ID: 19916726
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Efficacy and safety of rosuvastatin and atorvastatin in patients with hypercholesterolemia and a high risk of coronary heart disease: a randomized, controlled trial.
    Schwartz GG; Bolognese MA; Tremblay BP; Caplan R; Hutchinson H; Raza A; Cressman M
    Am Heart J; 2004 Jul; 148(1):e4. PubMed ID: 15215813
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical efficacy of rosuvastatin in lipid management in Chinese patients in Hong Kong.
    Lee VW; Chau TS; Leung VP; Lee KK; Tomlinson B
    Chin Med J (Engl); 2009 Dec; 122(23):2814-9. PubMed ID: 20092783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Lipid-altering efficacy of ezetimibe/simvastatin 10/20 mg compared with rosuvastatin 10 mg in high-risk hypercholesterolaemic patients inadequately controlled with prior statin monotherapy - The IN-CROSS study.
    Farnier M; Averna M; Missault L; Vaverkova H; Viigimaa M; Massaad R; Vandormael K; Johnson-Levonas AO; Brudi P
    Int J Clin Pract; 2009 Apr; 63(4):547-59. PubMed ID: 19222610
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Rosuvastatin and cardiovascular disease: did the strongest statin hold the initial promises?
    Efthimiadis A
    Angiology; 2008; 59(2 Suppl):62S-4S. PubMed ID: 18628276
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.